- Home
- SID vs KNSA Comparison
SID vs KNSA Comparison
Compare SID & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SID
- KNSA
- Stock Information
- Founded
- SID 1941
- KNSA 2015
- Country
- SID Brazil
- KNSA United Kingdom
- Employees
- SID N/A
- KNSA N/A
- Industry
- SID Steel/Iron Ore
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- SID Industrials
- KNSA Health Care
- Exchange
- SID Nasdaq
- KNSA Nasdaq
- Market Cap
- SID 2.0B
- KNSA 1.6B
- IPO Year
- SID 1997
- KNSA 2018
- Fundamental
- Price
- SID $1.45
- KNSA $20.36
- Analyst Decision
- SID Strong Sell
- KNSA Strong Buy
- Analyst Count
- SID 3
- KNSA 6
- Target Price
- SID $2.40
- KNSA $37.17
- AVG Volume (30 Days)
- SID 2.6M
- KNSA 534.6K
- Earning Date
- SID 05-07-2025
- KNSA 04-22-2025
- Dividend Yield
- SID 14.01%
- KNSA N/A
- EPS Growth
- SID N/A
- KNSA N/A
- EPS
- SID N/A
- KNSA N/A
- Revenue
- SID $7,063,567,739.00
- KNSA $423,239,000.00
- Revenue This Year
- SID $8.50
- KNSA $37.21
- Revenue Next Year
- SID $5.05
- KNSA $2.58
- P/E Ratio
- SID N/A
- KNSA N/A
- Revenue Growth
- SID N/A
- KNSA 56.60
- 52 Week Low
- SID $1.27
- KNSA $16.56
- 52 Week High
- SID $3.08
- KNSA $28.15
- Technical
- Relative Strength Index (RSI)
- SID 43.57
- KNSA 38.07
- Support Level
- SID $1.65
- KNSA $22.62
- Resistance Level
- SID $1.71
- KNSA $23.42
- Average True Range (ATR)
- SID 0.06
- KNSA 0.71
- MACD
- SID -0.02
- KNSA -0.34
- Stochastic Oscillator
- SID 3.85
- KNSA 5.82
About SID Companhia Siderurgica Nacional S.A.
Companhia Siderurgica Nacional is an integrated steel producer. The company operate throughout the entire steel production chain, from the mining of iron ore to the production and sale of a diversified range of steel products. It operates in five segments namely, Steel, Mining, Logistics, Energy, and Cement. It generates maximum revenue from the steel segment. Geographically, it derives a majority of revenue from Asia.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.